Last updated: July 31, 2026
Palonosetron hydrochloride is a second-generation 5-HT3 receptor antagonist used mainly to prevent chemotherapy-induced nausea and vomiting (CINV). The U.S. product market is mature and genericized, with limited standalone patent protection. Commercial growth is shifting from branded palonosetron injection toward generic hospital supply, fixed-dose combinations, oral products, and emerging-market oncology use. The strongest current commercial asset is the palonosetron component in Akynzeo, particularly the intravenous fixed-dose combination with fosnetupitant.
What is palonosetron hydrochloride approved to treat?
Palonosetron hydrochloride is approved for the prevention of:
- Acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy
- Acute nausea and vomiting associated with highly emetogenic chemotherapy
- Postoperative nausea and vomiting in adults, depending on formulation and jurisdiction
The FDA-approved intravenous product is administered as a 0.25 mg dose before chemotherapy. The postoperative nausea and vomiting dose is 0.075 mg administered before induction of anesthesia. The oral capsule contains 0.5 mg palonosetron hydrochloride and is approved for prevention of nausea and vomiting associated with moderately emetogenic chemotherapy in adults.[1]
Palonosetron has a longer elimination half-life than first-generation 5-HT3 antagonists. The extended exposure supports control of delayed CINV, although clinical practice commonly combines it with dexamethasone, an NK1 receptor antagonist, and, for selected patients, olanzapine.
How does palonosetron work?
Palonosetron selectively antagonizes the 5-HT3 receptor in the central nervous system and gastrointestinal tract. Its pharmacology is differentiated from ondansetron and granisetron by higher receptor affinity and a substantially longer half-life, reported at approximately 40 hours in adults.[1]
The drug does not prevent all forms of chemotherapy-related nausea. Its principal value is control of serotonin-mediated emesis, especially during the first several days after chemotherapy.
What is the current FDA regulatory status of palonosetron?
The FDA approved Aloxi, the original branded palonosetron injection, in 2003. The oral capsule was approved in 2008. Multiple generic palonosetron hydrochloride injections have since received FDA approval through abbreviated new drug applications.[2]
| Product or formulation |
U.S. regulatory position |
Principal use |
| Palonosetron hydrochloride injection, 0.25 mg/5 mL |
Generic products approved |
CINV prevention |
| Palonosetron hydrochloride injection, 0.075 mg/1.5 mL |
Generic products approved |
Postoperative nausea and vomiting |
| Palonosetron hydrochloride capsule, 0.5 mg |
Approved dosage form; limited commercial prominence |
Moderately emetogenic chemotherapy |
| Aloxi injection |
Originator brand; generic competition |
CINV and postoperative nausea and vomiting |
| Akynzeo oral capsule |
Active fixed-dose combination |
Netupitant/palonosetron for CINV |
| Akynzeo injection |
Active fixed-dose combination |
Fosnetupitant/palonosetron for CINV |
The FDA’s Orange Book remains relevant for the branded combination product and any listed patents or exclusivity attached to the combination. Standalone palonosetron injection is primarily a generic market.[3]
What patents protect palonosetron hydrochloride?
Standalone palonosetron hydrochloride has limited remaining patent value in the United States. The original compound and formulation patents have expired or are no longer meaningful barriers to generic entry. Current protection is concentrated in combination products, specific formulations, manufacturing processes, and jurisdiction-specific patent portfolios.
Key patent categories
| Patent category |
Commercial relevance |
Current barrier |
| Palonosetron compound patents |
Protected the active pharmaceutical ingredient |
Expired |
| Injectable formulation patents |
Covered concentration, stability, or presentation |
Mostly expired or commercially weak |
| Oral capsule patents |
Covered oral administration and formulation |
Limited standalone value |
| Combination patents |
Cover palonosetron with netupitant or fosnetupitant |
More relevant for Akynzeo |
| Manufacturing patents |
May cover intermediates, crystallization, or process controls |
Potentially relevant by jurisdiction |
| Method-of-use patents |
Cover selected CINV regimens or patient populations |
Narrow and difficult to enforce against standard generic injection |
The originator patent estate began with Helsinn Healthcare SA and related entities. Later commercial rights were associated with Helsinn and strategic partners, including Eisai for Akynzeo commercialization in several markets.
When did palonosetron lose U.S. exclusivity?
The principal U.S. compound protection for palonosetron expired before the current generic market matured. Generic palonosetron injection products entered the U.S. market in the late 2010s, eliminating meaningful exclusivity for the standalone active ingredient.
The exact legal position depends on dosage form, patent listing, pediatric extensions, and the applicant’s Paragraph IV certifications. A generic injection does not automatically invalidate patents protecting an oral combination or a netupitant/palonosetron product.
What is the Orange Book status of palonosetron?
The Orange Book distinguishes between standalone palonosetron products and fixed-dose combinations. This distinction is commercially important.
For standalone palonosetron hydrochloride injection, the principal patent barrier has fallen away and ANDA competition is established. For Akynzeo, Orange Book-listed patents may cover the combination, formulation, or method of use rather than palonosetron alone.[3]
An ANDA applicant seeking approval for a listed product may certify that:
- No patent information is listed;
- The patent has expired;
- The applicant will wait for patent expiration; or
- The listed patent is invalid, unenforceable, or will not be infringed.
A Paragraph IV certification can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework. The commercial effect depends on the patent claims, the timing of the certification, and whether the reference product is a standalone palonosetron product or a combination product.
Which companies compete in the palonosetron market?
The market has two distinct competitive segments.
Standalone palonosetron
Competition includes generic injectable manufacturers supplying hospitals, oncology clinics, wholesalers, and group purchasing organizations. Generic suppliers commonly compete on:
- Contract price
- Supply reliability
- Vial and presentation availability
- Shortage performance
- FDA compliance history
- Distribution relationships
The standalone product has low differentiation. Hospitals generally treat it as a procurement product rather than a branded therapeutic franchise.
Combination products
The principal differentiated product is Akynzeo, which combines palonosetron with an NK1 antagonist:
- Oral netupitant/palonosetron
- Intravenous fosnetupitant/palonosetron
These products target broader guideline-based prophylaxis for highly emetogenic chemotherapy and selected moderately emetogenic regimens. Their value is based on regimen simplification and broader antiemetic coverage, not on palonosetron’s standalone patent position.
| Product |
Components |
Strategic position |
| Palonosetron injection |
Palonosetron alone |
Low-cost generic antiemetic |
| Aloxi |
Palonosetron alone |
Originator reference product |
| Akynzeo oral |
Netupitant plus palonosetron |
Fixed-dose CINV prevention |
| Akynzeo IV |
Fosnetupitant plus palonosetron |
IV fixed-dose combination |
| Ondansetron products |
Ondansetron alone |
Low-cost first-generation competitor |
| Granisetron products |
Granisetron alone |
Generic 5-HT3 competitor |
| Rolapitant or aprepitant combinations |
NK1-based regimens |
Compete in guideline-driven CINV protocols |
What clinical trials are evaluating palonosetron?
Palonosetron is no longer a high-growth discovery-stage molecule. Current and recent clinical research is concentrated in comparative effectiveness, pediatric use, postoperative nausea and vomiting, combination regimens, and regional formulation development.
Main clinical-trial themes
Chemotherapy-induced nausea and vomiting
Studies continue to evaluate palonosetron in combination with:
- Dexamethasone
- Aprepitant or fosaprepitant
- Netupitant or fosnetupitant
- Olanzapine
- Chemotherapy-specific antiemetic protocols
The research question is usually regimen optimization rather than whether palonosetron has basic antiemetic activity. Trials often compare complete response rates over the acute, delayed, and overall phases.
Pediatric oncology
Pediatric trials assess weight-based dosing, tolerability, and comparative prevention of CINV. The principal development issue is dose selection and age-specific pharmacokinetics rather than a new mechanism.
Postoperative nausea and vomiting
Studies evaluate the 0.075 mg intravenous dose across surgical populations, including patients at elevated risk because of prior nausea, female sex, nonsmoking status, opioid exposure, or certain surgical procedures.
Fixed-dose combinations
The most commercially important research area is the development and expansion of palonosetron-containing NK1 combinations. These products seek to replace multi-drug administration with a single oral capsule or intravenous dose.
ClinicalTrials.gov lists palonosetron studies across oncology and perioperative settings, but the program is fragmented across sponsors and countries. No standalone palonosetron clinical development program currently indicates a major new U.S. indication comparable with an innovative oncology product.[4]
How strong is the palonosetron patent estate?
The standalone palonosetron estate is weak for generic entry. The combination-product estate is materially stronger but narrower.
| Estate |
Generic entry risk |
Explanation |
| Palonosetron injection |
High |
Multiple generic products and limited remaining exclusivity |
| Palonosetron oral capsule |
Moderate to high |
Limited market demand and limited differentiation |
| Palonosetron plus netupitant |
Moderate |
Combination patents and regulatory exclusivity may delay substitution |
| Fosnetupitant plus palonosetron IV |
Moderate |
Product-specific formulation and combination claims |
| Manufacturing processes |
Low to moderate |
Can affect supply, but often avoidable through alternative processes |
| Method-of-use claims |
Moderate |
Enforcement depends on labeling and inducement evidence |
The highest-value intellectual property is likely to remain in combination products and manufacturing know-how. Palonosetron itself is not a strong basis for long-term exclusivity.
What generic entry risks exist for palonosetron?
Standalone injection
Generic entry risk is already realized. The market is exposed to continued price erosion, tender competition, and supplier consolidation. Additional entrants can reduce pricing further, although shortages or manufacturing disruptions can temporarily improve margins.
Combination products
Akynzeo faces a different risk profile. A generic applicant may need to address patents covering:
- The combination of palonosetron and an NK1 antagonist
- Specific dosage ratios
- Oral or injectable formulations
- Treatment of delayed CINV
- Manufacturing and stability characteristics
A generic may attempt a Paragraph IV challenge, a section viii carve-out for protected methods, or a later launch after patent expiration. The litigation risk is higher than for standalone palonosetron, but the addressable market is smaller.
Biosimilar risk
Palonosetron is a small-molecule drug, not a biologic. Biosimilar competition is therefore not applicable. The relevant competitors are ANDA-approved generics and other branded or generic antiemetic combinations.
What is the palonosetron market size and commercial outlook?
Public company filings generally do not disclose global palonosetron revenue as a separate line item. Reported sales are often grouped within oncology supportive-care portfolios, generic injectable portfolios, or broader pharmaceutical segments.
The market can be divided into four revenue pools:
- Generic palonosetron injection
- Originator or branded palonosetron injection
- Oral palonosetron products
- Palonosetron-containing fixed-dose combinations
The first segment has the largest unit volume but the lowest pricing. The fourth segment has the strongest pricing and product differentiation.
Market drivers
- Continued use of moderately and highly emetogenic chemotherapy
- Growth in outpatient oncology infusion
- Increased use of guideline-based antiemetic prophylaxis
- Demand for single-dose or single-administration regimens
- Expansion of cancer treatment in emerging markets
- Hospital preference for reliable injectable supply
Market constraints
- Generic price competition
- Substitution by ondansetron and granisetron
- Limited clinical differentiation for standalone injection
- Purchasing-group pressure
- Increased use of multi-agent antiemetic protocols that shift value to NK1 antagonists and olanzapine
- Limited ability to raise price without supply disruption
What is the palonosetron market projection through 2030?
A product-level dollar forecast is less reliable than a segment-based model because manufacturers do not consistently report palonosetron revenue separately. A reasonable base-case projection uses 2024 revenue as an index of 100.
| Segment |
2024 index |
2030 base case |
2024-2030 outlook |
| Generic palonosetron injection |
100 |
85-100 |
Flat to declining value |
| Branded standalone injection |
100 |
45-65 |
Declining |
| Oral palonosetron |
100 |
70-90 |
Flat to declining |
| Palonosetron-NK1 combinations |
100 |
125-160 |
Growth |
| Total palonosetron-containing market |
100 |
95-125 |
Low single-digit range, highly mix-dependent |
The base case assumes rising oncology treatment volume but continued generic price erosion. The upside case depends on greater adoption of fixed-dose combinations and IV fosnetupitant/palonosetron. The downside case assumes accelerated substitution by low-cost 5-HT3 antagonists and weak uptake of branded combinations.
Revenue exposure is therefore asymmetric. Companies dependent on standalone palonosetron injection face volume stability but margin pressure. Companies holding differentiated combination products have higher revenue-per-patient potential but face patent litigation, reimbursement, and formulary risk.
What manufacturing and geographic IP barriers affect palonosetron?
Palonosetron hydrochloride is a mature small molecule with established synthetic routes and multiple global suppliers. Manufacturing barriers are more likely to involve quality systems, sterile injectable production, stability, and regulatory compliance than active-ingredient scarcity.
Geographic considerations
- United States: Generic competition is established; combination-product patents remain more important.
- Europe: National reimbursement and hospital tenders influence demand; patent status varies by country.
- Japan: Regulatory and commercial rights may differ from U.S. and European arrangements.
- China and India: Local manufacturing and lower-cost supply can increase volume but intensify price competition.
- Emerging markets: Injectable oncology growth can support unit expansion, but pricing is constrained.
Sterile manufacturing capacity is a more practical barrier than compound chemistry. A supplier with reliable fill-finish capacity can gain share during shortages even when the underlying API is widely available.
What patent litigation and settlement issues affect palonosetron?
Standalone palonosetron is not currently characterized by a major U.S. patent litigation campaign comparable with newer oncology drugs. Litigation exposure is more relevant to fixed-dose combinations and newer presentations.
Potential disputes generally involve:
- Validity of combination patents
- Obviousness of combining palonosetron with an NK1 antagonist
- Infringement by dosage ratio or formulation
- Written-description and enablement challenges
- Section viii labeling strategies
- 30-month stays following Paragraph IV certification
Settlement agreements, if reached, may establish a licensed launch date, supply arrangement, or restricted indication strategy. The business impact depends on whether the settlement preserves branded combination pricing or permits an earlier generic launch.
Key Takeaways
- Palonosetron hydrochloride is an established 5-HT3 antagonist with FDA-approved injectable and oral products.
- Standalone palonosetron injection is a mature generic market with high entry and price-erosion risk.
- The main commercial growth opportunity is in palonosetron-containing NK1 combinations, especially oral netupitant/palonosetron and IV fosnetupitant/palonosetron.
- Biosimilar risk does not apply because palonosetron is a small molecule.
- Standalone compound and formulation patents provide little current U.S. protection.
- Combination, formulation, method-of-use, and manufacturing patents remain the relevant barriers.
- Through 2030, total market value is likely to be flat to modestly positive, with revenue shifting from standalone injection to differentiated combinations.
- Clinical-trial activity is focused on regimen optimization, pediatric use, postoperative nausea and vomiting, and combination therapy rather than a new standalone palonosetron indication.
FAQs
Is palonosetron hydrochloride still under patent protection?
Standalone palonosetron hydrochloride has little meaningful remaining U.S. patent protection. Current patent risk is concentrated in fixed-dose combinations, formulations, methods of use, and manufacturing processes.
Can a generic palonosetron injection launch without challenging Akynzeo patents?
Yes. A generic standalone palonosetron injection does not necessarily infringe patents directed to netupitant/palonosetron or fosnetupitant/palonosetron combinations.
Is palonosetron stronger than ondansetron for delayed CINV?
Palonosetron has a longer half-life and is generally positioned more strongly for delayed CINV. Treatment guidelines still commonly recommend combination therapy for highly emetogenic chemotherapy.
Who owns the commercial rights to Akynzeo?
Akynzeo was developed by Helsinn and commercialized through regional partnerships, including Eisai in certain markets. Rights and distribution arrangements vary by jurisdiction.
Does palonosetron have an FDA-approved oral dosage form?
Yes. The FDA approved a 0.5 mg oral capsule for prevention of nausea and vomiting associated with moderately emetogenic chemotherapy in adults.
References
-
U.S. Food and Drug Administration. (2023). Aloxi (palonosetron hydrochloride) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2008). FDA approves oral Aloxi for prevention of chemotherapy-induced nausea and vomiting. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
National Library of Medicine. (2025). ClinicalTrials.gov search results for palonosetron. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
-
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Antiemesis. NCCN.
